Chemical formula: C₂₅H₂₆N₇O₈P Molecular mass: 583.498 g/mol PubChem compound: 11319217
Fostemsavir is a prodrug without significant antiviral activity that is hydrolysed to the active moiety, temsavir, upon cleavage of a phosphonooxymethyl group in vivo. Temsavir binds directly to the gp120 subunit within the HIV-1 envelope glycoprotein gp160 and selectively inhibits the interaction between the virus and cellular CD4 receptor, thereby preventing viral entry into, and infection of, host cells.
This medicinal substance has been classified in the anatomical therapeutic chemical (ATC) classification according to its main therapeutic use as follows:
| ATC Group | Classification | |
|---|---|---|
| J05AX29 | J Antiinfectives for systemic use → J05 Antivirals for systemic use → J05A Direct acting antivirals → J05AX Other antivirals | |
Competent medicine agencies globally have authorized commercialization of this active ingredient according to these medication package inserts (MPIs):
| Document | Type | Information Source | |
|---|---|---|---|
| RUKOBIA Prolonged-release tablet | MPI, EU: SmPC | European Medicines Agency (EU) | |
| RUKOBIA Extended-release tablet | MPI, US: SPL/PLR | FDA, National Drug Code (US) |
Fostemsavir is an active ingredient of these brands:
Austria (AT)
Croatia (HR)
Estonia (EE)
Finland (FI)
France (FR)
Ireland (IE)
Italy (IT)
Lithuania (LT)
Poland (PL)
Romania (RO)
Spain (ES)
United States (US)
Note the following: The list of brand names is continuously updated, and thus does not include the total of products circulating worldwide. |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.